KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Non Operating Income (2017 - 2025)

Ionis Pharmaceuticals (IONS) has 9 years of Non Operating Income data on record, last reported at -$1.0 million in Q4 2025.

  • For Q4 2025, Non Operating Income fell 3.25% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached -$118000.0, down 886.67%, while the annual FY2025 figure was -$118000.0, 886.67% down from the prior year.
  • Non Operating Income reached -$1.0 million in Q4 2025 per IONS's latest filing, down from $362000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.2 million in Q2 2023 and bottomed at -$13.9 million in Q4 2023.
  • Average Non Operating Income over 5 years is -$927850.0, with a median of $164500.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: plummeted 15273.33% in 2021, then soared 6133.33% in 2022.
  • A 5-year view of Non Operating Income shows it stood at -$9.1 million in 2021, then surged by 180.71% to $7.3 million in 2022, then tumbled by 288.88% to -$13.9 million in 2023, then skyrocketed by 92.69% to -$1.0 million in 2024, then fell by 3.25% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$1.0 million in Q4 2025, $362000.0 in Q3 2025, and $102000.0 in Q2 2025.